Price T Rowe Associates Inc. MD Boosts Stock Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Price T Rowe Associates Inc. MD lifted its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 5.8% in the first quarter, Holdings Channel.com reports. The fund owned 3,685,753 shares of the biopharmaceutical company’s stock after purchasing an additional 201,784 shares during the period. Price T Rowe Associates Inc. MD’s holdings in Alnylam Pharmaceuticals were worth $550,837,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds also recently made changes to their positions in ALNY. BOKF NA boosted its holdings in Alnylam Pharmaceuticals by 23.9% in the 1st quarter. BOKF NA now owns 6,712 shares of the biopharmaceutical company’s stock valued at $1,029,000 after purchasing an additional 1,295 shares during the period. Altitude Crest Partners Inc. bought a new stake in Alnylam Pharmaceuticals during the first quarter valued at $30,000. Canada Pension Plan Investment Board grew its position in Alnylam Pharmaceuticals by 12.7% during the first quarter. Canada Pension Plan Investment Board now owns 273,790 shares of the biopharmaceutical company’s stock worth $40,918,000 after buying an additional 30,792 shares in the last quarter. Capital Research Global Investors increased its stake in Alnylam Pharmaceuticals by 7.3% in the 1st quarter. Capital Research Global Investors now owns 3,144,987 shares of the biopharmaceutical company’s stock worth $470,018,000 after acquiring an additional 214,908 shares during the last quarter. Finally, Capital International Investors raised its holdings in shares of Alnylam Pharmaceuticals by 1.8% in the 1st quarter. Capital International Investors now owns 3,651,217 shares of the biopharmaceutical company’s stock valued at $545,674,000 after acquiring an additional 64,560 shares in the last quarter. 92.97% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

ALNY has been the subject of several recent analyst reports. UBS Group boosted their price objective on Alnylam Pharmaceuticals from $253.00 to $288.00 and gave the stock a “buy” rating in a report on Friday, June 28th. SVB Leerink increased their price target on shares of Alnylam Pharmaceuticals from $138.00 to $159.00 and gave the stock a “market perform” rating in a report on Tuesday, June 25th. BMO Capital Markets reaffirmed an “outperform” rating and set a $234.00 price objective on shares of Alnylam Pharmaceuticals in a report on Monday, June 24th. Wells Fargo & Company upped their target price on shares of Alnylam Pharmaceuticals from $161.00 to $207.00 and gave the stock an “equal weight” rating in a research report on Tuesday, June 25th. Finally, Evercore ISI raised their price target on Alnylam Pharmaceuticals from $210.00 to $260.00 and gave the company an “outperform” rating in a research report on Tuesday, June 25th. Eight investment analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $256.73.

Alnylam Pharmaceuticals Price Performance

ALNY traded up $0.01 during mid-day trading on Monday, reaching $234.85. 56,820 shares of the company traded hands, compared to its average volume of 876,563. Alnylam Pharmaceuticals, Inc. has a 52-week low of $141.98 and a 52-week high of $263.73. The company’s fifty day moving average price is $198.99 and its 200-day moving average price is $172.41.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings data on Thursday, May 2nd. The biopharmaceutical company reported ($0.52) EPS for the quarter, topping the consensus estimate of ($0.75) by $0.23. The company had revenue of $494.33 million during the quarter, compared to analysts’ expectations of $428.01 million. During the same quarter last year, the company earned ($1.40) earnings per share. The company’s revenue for the quarter was up 54.8% on a year-over-year basis. On average, equities analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -3.99 EPS for the current year.

Insider Transactions at Alnylam Pharmaceuticals

In other news, EVP Kevin Joseph Fitzgerald sold 1,198 shares of the business’s stock in a transaction on Tuesday, June 25th. The shares were sold at an average price of $230.99, for a total value of $276,726.02. Following the transaction, the executive vice president now owns 14,181 shares of the company’s stock, valued at $3,275,669.19. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In other Alnylam Pharmaceuticals news, Director David E. I. Pyott sold 32,450 shares of the business’s stock in a transaction that occurred on Monday, June 24th. The stock was sold at an average price of $220.69, for a total transaction of $7,161,390.50. Following the sale, the director now directly owns 136 shares of the company’s stock, valued at $30,013.84. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Kevin Joseph Fitzgerald sold 1,198 shares of the company’s stock in a transaction that occurred on Tuesday, June 25th. The shares were sold at an average price of $230.99, for a total value of $276,726.02. Following the sale, the executive vice president now owns 14,181 shares in the company, valued at $3,275,669.19. The disclosure for this sale can be found here. Insiders sold a total of 74,450 shares of company stock valued at $15,287,984 over the last 90 days. Company insiders own 1.50% of the company’s stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.